How CLN4 Disease Works and Look-Alikes
At a Glance
CLN4 disease is caused by a DNAJC5 mutation that changes CSP-alpha, a protein helper in nerve cells. The altered protein disrupts cellular recycling and nerve signaling, causing harmful ceroid buildup; diagnosis may require specialized genetic testing and comparison with similar disorders.
Understanding how CLN4 (Kufs disease) works requires looking deep into the brain’s waste-management system. Unlike many other neurological conditions that involve the buildup of toxic proteins like amyloid or tau, CLN4 is a disorder of cellular trafficking—the way your brain cells move and process essential materials [1][2].
The Biological Engine: DNAJC5 and CSPα
Every case of CLN4 is caused by a mutation in the DNAJC5 gene. This gene provides the instructions for making a protein called Cysteine-String Protein-alpha (CSPα) [3].
In a healthy brain, CSPα acts as a “molecular chaperone” [4]. It helps fold and protect other proteins that are essential for synaptic transmission—the process by which nerve cells talk to each other [5]. In CLN4, the mutated CSPα is thought to become “sticky” and toxic. It may form clumps (oligomers) and get stuck in the wrong parts of the cell, failing to guide the proteins it was supposed to protect [1][2].
Why “Storage” Happens
When CSPα fails, the cell’s internal cleaning and transport systems may break down. This leads to the accumulation of ceroid and lipofuscin [6].
- Impaired Membrane Trafficking: The cell may no longer move waste materials efficiently to its recycling centers (lysosomes) [7].
- Abnormal Protein Processing: Essential proteins for nerve communication, such as SNAP-25, may not be folded correctly, leading to “synaptic dysfunction” where cells can’t send signals properly [4][5].
- Lysosomal Damage: As the mutated CSPα clumps together, it may physically damage the membranes of the cell’s recycling centers, causing them to leak and fail [8].
Pathological Ceroid vs. Normal Aging
You may hear doctors talk about lipofuscin as “wear-and-tear pigment.” This substance naturally accumulates in all of us as we age. However, there is a critical difference between normal aging and CLN4:
- Normal Aging: Lipofuscin builds up slowly over decades and generally doesn’t interfere with how brain cells function until very late in life.
- CLN4 Storage: This is “pathological” storage. It is much more aggressive, accumulates in massive amounts, and is directly linked to the cell-killing toxicity of the DNAJC5 mutation [9]. In CLN4, this material is often called ceroid to distinguish its harmful nature from normal aging pigment [10].
Telling CLN4 Apart from “Look-Alikes”
Because the early symptoms of CLN4—like seizures, movement problems, or cognitive decline—are seen in many other diseases, misdiagnosis is common. Doctors must carefully distinguish CLN4 from several other conditions. Note: The table below is for educational purposes only. Diagnosis always requires expert clinical, genetic, and sometimes biomarker interpretation.
| Condition | Distinguishing Factors from CLN4 |
|---|---|
| Early-Onset Alzheimer’s | Primarily involves memory loss and is characterized by amyloid plaques and tau tangles, which are usually absent in CLN4 [10][3]. |
| Huntington Disease | Caused by a different gene mutation (HTT) and involves specific, choreic (dance-like) movements and a different pattern of brain shrinkage [10]. |
| CLN6 / CTSF | These are other forms of adult NCL (Kufs). They are usually recessive (requiring two mutated genes) and often show different patterns on an MRI, such as significant shrinkage of the cerebellum [11][12]. |
| Prion Disease | Often progresses much more rapidly (weeks or months) than CLN4 and has distinct markers in spinal fluid tests [10]. |
| Niemann-Pick Type C | Primarily affects the body’s ability to move cholesterol and often includes an inability to look up or down (vertical supranuclear gaze palsy) [10]. |
The Diagnostic Challenge
Diagnosis is often difficult because the most common genetic sequencing tests can sometimes “miss” the specific type of variants (like certain insertions or duplications) found in the DNAJC5 gene [13]. If a test comes back negative but symptoms strongly suggest CLN4, doctors may need to use more specialized genetic techniques to find the mutation [14]. While focusing on a dominant family history (where one parent also had symptoms) is often a big clue that points toward CLN4, a lack of family history does not exclude CLN4 because de novo (spontaneous) mutations can occur [3].
Common questions in this guide
What causes CLN4 disease?
Is the ceroid buildup in CLN4 the same as normal lipofuscin from aging?
Can genetic testing miss CLN4 disease?
How do doctors distinguish CLN4 from Alzheimer disease or Huntington disease?
Can CLN4 occur without a family history?
What other diseases can resemble CLN4?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given that standard genetic tests can miss specific DNAJC5 variants, was my test a high-sensitivity sequencing or did it include a targeted search for specific insertions or duplications?
- 2.Since CLN4 can look like early-onset Alzheimer's or Huntington disease, were these conditions specifically ruled out through genetic or biomarker testing?
- 3.If a skin or tissue biopsy was performed, was the material reviewed by a specialist who can distinguish pathological ceroid from normal age-related lipofuscin?
- 4.Does my brain imaging show the specific patterns of atrophy often seen in CLN6 or CTSF, or does it more closely align with the early preservation of brain structure seen in some DNAJC5 cases?
- 5.Are there specific 'red flag' symptoms I should watch for that would suggest a different diagnosis, such as rapid vision changes or unique movement patterns?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis.
Diez-Ardanuy C, Greaves J, Munro KR, et al.
Scientific reports 2017; (7(1)):10 doi:10.1038/s41598-017-00036-8.
PMID: 28127059 - 2
A Drosophila model of neuronal ceroid lipofuscinosis CLN4 reveals a hypermorphic gain of function mechanism.
Imler E, Pyon JS, Kindelay S, et al.
eLife 2019; (8()).
PMID: 31663851 - 3
Evidence for Cholinergic Dysfunction in Autosomal Dominant Kufs Disease.
Jarrett P, Easton A, Rockwood K, et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2018; (45(2)):150-157 doi:10.1017/cjn.2017.261.
PMID: 29506599 - 4
Cysteine string protein (CSP) and its role in preventing neurodegeneration.
Burgoyne RD, Morgan A
Seminars in cell & developmental biology 2015; (40()):153-9.
PMID: 25800794 - 5
Proximity labelling reveals effects of disease-causing mutation on the DNAJC5/cysteine string protein α interactome.
Barker E, Milburn A, Helassa N, et al.
The Biochemical journal 2024; doi:10.1042/BCJ20230319.
PMID: 38193346 - 6
Abnormal triaging of misfolded proteins by adult neuronal ceroid lipofuscinosis-associated DNAJC5/CSPα mutants causes lipofuscin accumulation.
Lee J, Xu Y, Saidi L, et al.
Autophagy 2023; (19(1)):204-223 doi:10.1080/15548627.2022.2065618.
PMID: 35506243 - 7
Primary fibroblasts from CSPα mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis.
Benitez BA, Sands MS
Scientific reports 2017; (7(1)):6332 doi:10.1038/s41598-017-06710-1.
PMID: 28740222 - 8
CHIP protects lysosomes from CLN4 mutant-induced membrane damage.
Lee J, Chin N, Zou J, et al.
Nature cell biology 2025; (27(9)):1465-1481 doi:10.1038/s41556-025-01738-2.
PMID: 40855364 - 9
Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss.
Benitez BA, Cairns NJ, Schmidt RE, et al.
Acta neuropathologica communications 2015; (3()):73 doi:10.1186/s40478-015-0256-5.
PMID: 26610600 - 10
Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease).
Berkovic SF, Staropoli JF, Carpenter S, et al.
Neurology 2016; (87(6)):579-84 doi:10.1212/WNL.0000000000002943.
PMID: 27412140 - 11
Brain imaging in Kufs disease type B: case reports.
Di Fabio R, Colonnese C, Santorelli FM, et al.
BMC neurology 2015; (15()):102 doi:10.1186/s12883-015-0357-6.
PMID: 26141065 - 12
Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD.
van der Zee J, Mariën P, Crols R, et al.
Neurology. Genetics 2016; (2(5)):e102 doi:10.1212/NXG.0000000000000102.
PMID: 27668283 - 13
Autosomal-dominant adult neuronal ceroid lipofuscinosis caused by duplication in DNAJC5 initially missed by Sanger and whole-exome sequencing.
Jedličková I, Cadieux-Dion M, Přistoupilová A, et al.
European journal of human genetics : EJHG 2020; (28(6)):783-789 doi:10.1038/s41431-019-0567-2.
PMID: 31919451 - 14
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.
Mole SE, Anderson G, Band HA, et al.
The Lancet. Neurology 2019; (18(1)):107-116 doi:10.1016/S1474-4422(18)30368-5.
PMID: 30470609
This page is for informational purposes only and does not constitute medical advice. A neurologist or genetics specialist should interpret your symptoms, imaging, tissue findings, and genetic testing.
Get notified when new evidence is published on CLN4 disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.